

**Oxfordshire Area Prescribing Committee (APCO) Bullet Points May 2016**

Prescribing Points and the Traffic light system are available on the OCCG website-link below. These bullet points summarise the decisions taken at APCO in May 2016.

**Local Guidance:** [Traffic Light Document](#)

The classifications are:

- Red List – Specialist Prescribing Only
- Yellow (Near Patient Testing LES) – Transfer of prescribing to primary care in line with Shared Care Protocol. Monitoring in Primary Care
- Yellow – Transfer of prescribing to primary care. Monitoring in secondary care
- Yellow Continuation List – Appropriate for continuation in primary care following specialist recommendation
- Brown – Prescribe only in restricted circumstances
- Black – Not recommended for use in primary or secondary care
- Holding List – Pending APCO / Priorities Forum decision

Drug	Traffic Light Classification	Rationale
Alfentanil	RED	Changed from yellow (shared care) due to low numbers of patients. Patient Specific Protocols can be used instead
Ketamine	RED	As for Alfentanil
<b>Sunscreens:</b>		
Anthelios® XL SPF 50+ Melt-in cream	BROWN	For specific ACBS conditions. For use on hands and face only. Up to 4 applications a day
Sunsense®Ultra Lotion (UVA and UVB, UVB-SPF50+	BROWN	As for Anthelios
Uvistat® (UVA and UVB protection; UVB-SPF 50)	BROWN	As for Anthelios
All other sunscreens	BLACK	
Ruxolitinib	RED	<a href="#">NICE TA386</a> <b>Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis.</b> RED for this TA but remains BLACK for treating polycythaemia vera under terminated appraisal TA356
Abiraterone	RED	<a href="#">NICE TA387</a> <b>Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.</b> <b>Action:</b> Traffic light RED – currently RED for TA259 which is still in place.
Sacubitril valsartan	RED	<a href="#">NICE TA388</a> <b>Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction</b>

Jane Bennett and Odelia Eke (May 2016 APCO recommendations ratified at June OCCG Clinical Ratification Group)

Drug	Traffic Light Classification	Rationale
Topotecan	BLACK	For <a href="#">TA389</a> Recurrent Ovarian Cancer. Remains RED for TA184 SCLC
Pegylated liposomal doxorubicin HCl	RED	For <a href="#">TA389</a> Recurrent Ovarian Cancer
Paclitaxel	RED	For <a href="#">TA389</a> Recurrent Ovarian Cancer. RED for TA55 ovarian cancer, BLACK for TA 362 NSCLC, TA360 metastatic pancreatic cancer, TA284 advanced ovarian cancer and TA108 breast cancer
Trabectedin	BLACK	For <a href="#">TA389</a> Recurrent Ovarian Cancer. Remains RED for TA185 soft tissue carcinoma
Gemcitabine	BLACK	For <a href="#">TA389</a> Recurrent Ovarian Cancer BLACK for TA285 ovarian cancer, TA360 untreated metastatic pancreatic cancer. Remains RED for TA25 pancreatic cancer and TA116, breast cancer
Guanfacine	RED	<a href="#">ESNM70</a>
Dimethylfumarate	RED	A monitoring protocol to be produced
Tolvaptan	RED	For polycystic kidney disease
Tolvaptan	BLACK	for indications other than polycystic kidney disease
Blephaclean wipes	BLACK	Can be purchased through opticians, pharmacies and supermarkets
Vortioxetine	YELLOW	Continuation
Vardenafil, tadalafil, avanafil, Viagra®	BROWN	For patients who fulfil the SLS criteria. And for whom generic sildenafil is ineffective. Max doses 2 per month as per <a href="#">Lavender Statement 41d</a>
Prostaglandin E1 intracavernosal injections and intraurethral instillations	BROWN	Recommended for patients who meet the SLS criteria AND only if oral phosphodiesterase type-5 inhibitors are contraindicated or ineffective. The maximum frequency of dosing should be two times per month using the drug with the lowest acquisition cost.as per <a href="#">Lavender Statement 41d</a>
Alprostadil Cream	BLACK	As per <a href="#">Lavender Statement 41d</a> due to limited evidence for clinical and cost effectiveness (only for new patients)
Vacuum Erection Devices	BLACK	As per <a href="#">Lavender Statement 41d</a> due to limited evidence for clinical and cost effectiveness (only for new patients)
Penile Implants	BLACK	As per <a href="#">Lavender Statement 41d</a> due to limited evidence for clinical and cost effectiveness (only for new patients)

• **Holding List Update**

<b>Drug</b>	<b>Traffic Light Classification Agreed</b>	<b>Rationale</b>
Jaydess 13.5 mg intrauterine delivery system	Holding List	Awaiting Public Health review
Alirocumab for hyperlipidaemia (primary) and dyslipidaemia (mixed)	Holding list	Remain on the holding list until NICE had assessed this under the Technology Appraisal programme
Ivermectin	Holding List	To be reconsidered in July meeting
Cangrelor	Holding List	

**Local Guidance and Shared Care**

**1. Insulin Safety Alert**

An insulin safety alert was presented by OUHFT. This bulletin raises the importance of prescribing insulin by brand, ensuring that the correct strength of insulin and the correct device are both stated on the prescription. The bulletin also raises awareness that insulin should NEVER be withdrawn from a penfill, cartridge or disposable pen using an insulin syringe. The alert is available on the OUH website at <http://orh.oxnet.nhs.uk/AdultInpatientDiabetes/Pages/Default.aspx> and will be circulated in Prescribing Points.

**2. Update to antibiotic guidelines**

The vaccines required post splenectomy have changed. The antibiotic guidelines will be updated to include a link to The Green Book.

**3. Sunscreen Guidelines**

Local guidelines for the use of sunscreens have been written and approved by APCO. The guidelines recommend prescribing a maximum of 200ml per month for specific ABCS conditions eg abnormal photosensitivity resulting from a genetic disorder, vitiligo, photodermatoses resulting from radiotherapy and Lupus, both cutaneous and systemic. The recommended sunscreens are all UVA and UVB protection, SPF 50+

- Anthelios®XL Melt-in cream
- Sensense® Ultra Lotion
- Uvistat®